Irbesartan

Research use only, not for human use.

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension.

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of Y. (In Vitro):Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro.Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro.Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro.(In Vivo):Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice.Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects. Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II.Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice.

——

——

BMS 186295 | SR 47436

Endocrinology/Hormones

RAAS

AT1 receptor

Cardiovascular Disease

——

138402-11-6

428.54

C25H28N6O

>98% (HPLC)

Ethanol: 3 mg/mL (7.0 mM); DMSO: 1 mg/mL (2.33 mM)

CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

——

(-20℃)

With Ice Pack

≥ 2 years